1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015
Table of Contents
Introduction 6
Non-Rhabdomyosarcoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Rhabdomyosarcoma 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Non-Rhabdomyosarcoma Therapeutics Clinical Trials 31
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Zeltia, S.A. 34
Clinical Trial Overview of Zeltia, S.A. 34
GlaxoSmithKline plc 35
Clinical Trial Overview of GlaxoSmithKline plc 35
Johnson and Johnson 36
Clinical Trial Overview of Johnson and Johnson 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Novartis AG 38
Clinical Trial Overview of Novartis AG 38
Merck and Co., Inc. 39
Clinical Trial Overview of Merck and Co., Inc. 39
Daiichi Sankyo Company, Limited 40
Clinical Trial Overview of Daiichi Sankyo Company, Limited 40
Clinical Trial Overview of Top Institutes / Government 41
National Cancer Institute 41
Clinical Trial Overview of National Cancer Institute 41
European Organization for Research and Treatment of Cancer 42
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 42
Children's Oncology Group 43
Clinical Trial Overview of Children's Oncology Group 43
Memorial Sloan Kettering Cancer Center 44
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 44
Fred Hutchinson Cancer Research Center 45
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 45
University of Heidelberg 46
Clinical Trial Overview of University of Heidelberg 46
Massachusetts General Hospital 47
Clinical Trial Overview of Massachusetts General Hospital 47
Institut Bergonie 48
Clinical Trial Overview of Institut Bergonie 48
Five Key Clinical Profiles 49
Appendix 77
Abbreviations 77
Definitions 77
Research Methodology 78
Secondary Research 78
About GlobalData 79
Contact Us 79
Disclaimer 79
Source 79

List of Tables
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region, 2015* 7
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Non-Rhabdomyosarcoma Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Non-Rhabdomyosarcoma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Non-Rhabdomyosarcoma Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Non-Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 33
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Zeltia, S.A., 2015* 34
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2015* 35
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2015* 36
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 37
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 38
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2015* 39
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2015* 40
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 41
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2015* 42
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2015* 43
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 44
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2015* 45
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Heidelberg, 2015* 46
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2015* 47
Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut Bergonie, 2015* 48

List of Figures
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Non-Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

  • $ 5274
  • Industry report
  • September 2016
  • by Industry ARC

Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse ...

Global Clinical Trials Market

December 2016 $ 4250

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.